Latest News on GERN

Financial News Based On Company


Advertisement
Advertisement

Three new hires get options to buy 150,000 Geron shares at $1 each

https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-ir8uj8rffyvo.html
Geron Corporation announced that it granted stock options for 150,000 shares of common stock to three new employees as an inducement for their employment. The options have an exercise price of $1.00 per share, equal to the closing price on the grant date, and vest over four years. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

After his November 13 purchase, Geron (GERN) CEO holds 53,500 shares directly.

https://www.stocktitan.net/sec-filings/GERN/form-4-geron-corp-insider-trading-activity-943b62b35f26.html
Geron Corp (GERN) President & CEO Harout Semerjian purchased 53,500 common shares on November 13, 2026. After this transaction, his directly held position in the company is 53,500 shares. The shares were bought at a weighted-average price of $0.9500 per share, with individual transaction prices ranging from $0.9516 to $0.95470.

Geron Targets Germany Launch and Deals as RYTELO Sales Grow

https://www.tradingview.com/news/marketbeat:83dfa6962094b:0-geron-targets-germany-launch-and-deals-as-rytelo-sales-grow/
Geron is strategically expanding the market for its blood cancer drug RYTELO, focusing on increased U.S. adoption among community physicians and preparing for a commercial launch in Germany before year-end. The company reported its fourth consecutive quarter of growth, with net revenue exceeding $60 million, and is exploring potential deals for advanced-stage hematology or oncology assets after discontinuing a late-stage trial. Geron aims to maintain financial discipline while building international infrastructure and believes it has sufficient cash for future operations.

Nearly 32 million Geron (GERN) shares make up State Street's reported stake.

https://www.stocktitan.net/sec-filings/GERN/schedule-13g-geron-corp-passive-investment-disclosure-5-52db331a95d9.html
State Street Corporation has reported a 5% beneficial ownership stake in Geron (GERN) through a Schedule 13G SEC filing. This includes shared voting power over approximately 30.18 million shares and shared dispositive power over 31.89 million shares. The filing indicates a neutral sentiment and impact on Geron stock.

Geron Corp (GON.HM) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/GON.HM/
This Yahoo Finance page provides a detailed overview of Geron Corp (GON.HM) stock, including its current price, historical data, and key financial statistics. As of November 6, 2026, the stock closed at 0.7982 EUR, down 10.92%, with performance metrics spanning from one day to five years. The page also offers a comparison of Geron Corp's returns against the S&P 500 benchmark.
Advertisement

Geron Returns to Quarterly Profit as Rytelo Drives Q3 Revenue Growth

https://www.tokenpost.com/news/business/49047
Geron Corporation reported a quarterly profit in Q3 2026, ending a series of losses due to strong revenue growth from its blood cancer drug, Rytelo. This positive financial turnaround caused the company's shares to rise over 10% in early premarket trading, despite previous concerns about the drug's efficacy that led to the termination of a late-stage study.

Geron Corp (GERN) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/motley/8662746/geron-corp-gern-q3-2026-earnings-call-transcript/
Geron Corporation reported its first profitable quarter as a commercial-stage biopharmaceutical company, driven by a 27% year-over-year growth in RYTELO net product revenue to $60.1 million and a 9% reduction in operating expenses. The company reaffirmed its full-year 2026 revenue guidance of $220 million to $240 million and lowered its operating expense guidance to $220 million to $230 million. Following the discontinuation of the IMpactMF trial, Geron plans to focus on deepening RYTELO's penetration in the U.S. community oncology market, launching in Germany by late 2026, and actively pursuing business development opportunities in hematology and oncology.

Geron Corp (GERN) Q3 2026 Earnings Call Highlights: RYTELO Revenue Climbs 27% as Cost Cuts Lift ...

https://sg.finance.yahoo.com/news/geron-corp-gern-q3-2026-230733806.html
Geron Corp announced strong Q3 2026 results, with RYTELO net product revenue reaching $60.1 million, a 27% year-over-year increase, driven by a 10% quarter-over-quarter demand growth. The company also lowered its full-year 2026 operating expense guidance due to significant cost reductions. Despite the discontinuation of the Phase III IMpactMF trial, Geron is expanding RYTELO's presence in Europe and actively pursuing strategic business development opportunities.

Geron Corp (GERN) Tops Q3 EPS by 1c

https://www.streetinsider.com/Earnings/Geron+Corp+%28GERN%29+Tops+Q3+EPS+by+1c/27285756.html
Geron Corp (GERN) reported its Q3 earnings, surprising analysts by topping EPS estimates by $0.01 with a reported $0.00 EPS against an expected ($0.01). However, the company's revenue for the quarter, at $60.19 million, fell slightly short of the consensus estimate of $60.69 million.

Form 8K Geron Corporation For: 4 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-geron-corporation-for-4-november-93CH-4956219
Geron Corporation filed a Form 8K for November 4th, a regulatory filing typically used to announce significant events that investors should know about. The article from Investing.com provides this brief update along with various market data and other news. The specific details of the 8K filing are not provided within this summary article.
Advertisement

Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights

https://www.globenewswire.com/news-release/2026/11/04/3395186/0/en/geron-corporation-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html
Geron Corporation announced strong third-quarter 2026 financial results, achieving $60.1 million in RYTELO net product revenue and reiterating its full-year revenue guidance. The company also initiated a gated commercial launch to expand RYTELO's availability to eligible LR-MDS patients in targeted European markets, with Germany expected by year-end. Additionally, Geron reported a net income of $1.4 million for the quarter and decreased total operating expenses.

What Investors Got Wrong About Geron Before The Drop

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gern/geron/news/what-investors-got-wrong-about-geron-before-the-drop
Geron shares have fallen 29.5% since the start of 2026, prompting a re-evaluation of earlier assumptions. While Q2 2026 revenue for their single drug, RYTELO, exceeded expectations, the company still reported a loss, leaving the bullish profitability case unproven. The article suggests that Geron's current trading price of US$0.93 still implies confidence in RYTELO's market penetration despite past setbacks, highlighting the risks of a single-therapy business model.

A live webcast will carry Geron’s conference chat on Nov. 10.

https://www.stocktitan.net/news/GERN/geron-corporation-to-participate-in-the-stifel-2026-healthcare-0w609dra3xw1.html
Geron Corporation announced its management is scheduled to participate in the Stifel 2026 Healthcare Conference on November 10, 2026, including a fireside chat and one-on-one meetings. A live and archived audio webcast of the fireside chat will be accessible through the Investor section of Geron's website. The company, focused on hematology, also provided details about its RYTELO® (imetelstat) medicine for lower-risk myelodysplastic syndromes.

Wedbush cuts Geron stock price target to $5 on study halt

https://www.investing.com/news/analyst-ratings/wedbush-cuts-geron-stock-price-target-to-5-on-study-halt-93CH-4979976
Wedbush has lowered its price target for Geron Corporation (NASDAQ:GERN) to $5.00 from $6.00, while maintaining an Outperform rating, following the discontinuation of the company's IMpactMF study. Despite the study halt, Wedbush does not view it as a fundamental indictment of imetelstat’s biology and believes the commercial trajectory for Rytelo remains intact, especially given its strong NCCN treatment status and recent revenue performance. The firm removed MF from its financial model, which had previously represented approximately $130 million in sales by 2028.

Geron Corp (GON.MU) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/GON.MU/earnings-calls/
This article provides an overview of Geron Corp (GON.MU) stock performance, displaying its current price, historical data, and key financial statistics. As of October 30, the stock was trading at 0.8536 EUR, down 0.91%. The article also includes comparative trailing total returns against the S&P 500 benchmark.
Advertisement

Geron discontinues Phase III IMpactMF after survival futility assessment

https://allsci.com/news/biotech/imetelstat-myelofibrosis-geron-halts-phase-iii/
Geron Corporation has discontinued its Phase III IMpactMF trial for imetelstat (RYTELO) in JAK inhibitor-relapsed/refractory myelofibrosis after an independent Data Monitoring Committee determined the trial was unlikely to meet its primary overall survival endpoint. Although no new safety signals were reported, the trial's discontinuation means Geron will not expand imetelstat's existing approvals to this patient group. The company still has an ongoing Phase I/Ib combination trial of imetelstat with ruxolitinib in myelofibrosis.

Geron’s Rytelo Expansion Into Myelofibrosis Thwarted As Trial Discontinued

https://insights.citeline.com/scrip/therapeutic-category/anticancer/gerons-rytelo-expansion-into-myelofibrosis-thwarted-as-trial-discontinued-QIJJLGV4FFAMNAL5ERKNPMSX2U/
Geron has announced the discontinuation of its Phase III IMpactMF trial for Rytelo (imetelstat) in myelofibrosis. A data monitoring committee determined the trial was unlikely to meet its primary endpoint of improving overall survival, causing Geron's shares to fall sharply. This decision leaves Rytelo with only its myelodysplastic syndromes indication.

Geron Scraps Phase 3 Myelofibrosis Trial, Shares Fall 12%

https://finance.biggo.com/news/ee11ea3a-3fa9-4d84-914c-1cc884c86966
Geron Corporation announced the discontinuation of its Phase 3 IMpactMF trial for imetelstat in relapsed or refractory myelofibrosis, following a recommendation from an independent Data Monitoring Committee that the study was unlikely to meet its primary overall survival endpoint. This news led to a 12% drop in Geron's shares. The company plans to analyze the trial data and present findings later, while focusing on the commercial growth of its approved therapy, RYTELO.

Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth

https://www.benzinga.com/markets/biotech/26/10/62667978/penny-stock-geron-ends-advanced-cancer-study-shifts-focus-to-commercial-growth
Geron Corporation (NASDAQ: GERN) shares dropped after the company discontinued its Phase 3 IMpactMF trial for imetelstat in myelofibrosis, based on an independent panel's recommendation that the study was unlikely to meet its primary endpoint of overall survival. Despite this setback, Geron's leadership emphasized a shift in focus towards commercial growth for its RYTELO product and pursuing an innovation strategy to build a leading hematology company.

Form 8-K GERON CORP For: Oct 28

https://www.streetinsider.com/SEC+Filings/Form+8-K+GERON+CORP+For%3A+Oct+28/27250093.html
Geron Corporation filed a Form 8-K with the SEC on October 28, 2026, to provide an update on its Phase 3 IMpactMF clinical trial. This trial is evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. A press release detailing the update is attached as an exhibit to the filing.
Advertisement

A blood cancer trial is set to stop after monitors say it is unlikely to meet its survival goal.

https://www.stocktitan.net/news/GERN/geron-corporation-provides-update-on-phase-3-i-mpact-mf-clinical-w87pf2yz7trm.html
Geron (Nasdaq: GERN) announced the discontinuation of its Phase 3 IMpactMF trial for imetelstat in relapsed or refractory myelofibrosis. An independent Data Monitoring Committee recommended stopping the trial as it was unlikely to meet its primary endpoint of overall survival. Despite the discontinuation, Geron reported no new safety signals and remains committed to its commercial plans for RYTELO in lower-risk myelodysplastic syndromes.

Geron Corporation Provides Update on Phase 3 IMpactMF

https://www.globenewswire.com/news-release/2026/10/28/3390096/35501/en/geron-corporation-provides-update-on-phase-3-impactmf-clinical-trial-of-imetelstat-in-relapsed-refractory-myelofibrosis.html
Geron Corporation has decided to discontinue its Phase 3 IMpactMF trial for imetelstat in relapsed/refractory myelofibrosis, based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, though no new safety signals were observed. Geron remains committed to analyzing the data and growing demand for its approved medicine, RYTELO, for lower-risk myelodysplastic syndromes.

Geron Corp (GON.MU) Analyst insights, Price targets and Recommendations

https://uk.finance.yahoo.com/quote/GON.MU/analyst-insights/
This article provides an overview of recent analyst ratings and price target adjustments for Geron Corp (GON.MU). It details several upgrades, downgrades, and reiterations from various financial institutions like Needham, Scotiabank, HC Wainwright & Co., and Stifel, along with the corresponding dates. The company's current stock performance is also briefly mentioned.

From science to scale: How biopharma Geron transformed with RSM

https://www.rsmus.com/insights/industries/life-sciences/from-science-to-scale-how-biopharma-geron-transformed-with-rsm
Geron Corp., a biopharmaceutical company specializing in hematology, successfully transitioned from a development-stage company to a commercial enterprise with the help of RSM US LLP. RSM provided comprehensive services, including ERP implementation, accounting, inventory management, and tax planning, allowing Geron to scale rapidly and efficiently. This partnership led to significant cost savings and enabled Geron to maintain its focus on scientific innovation and patient care.

Geron Corporation Estimates – NASDAQ:GERN

https://www.tradingview.com/symbols/NASDAQ-GERN/financials-estimates/
This article provides an overview of Geron Corporation's (NASDAQ: GERN) financial information available on TradingView, including actual financial data and analyst estimates across various statements and valuation metrics. It highlights the ability to compare actual results with average, high, and low estimates and visualize trends over time. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
Advertisement

Geron Corporation to Report Third Quarter 2026 Financial Results on November 4, 2026

https://www.quiverquant.com/news/Geron+Corporation+to+Report+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026
Geron Corporation (Nasdaq: GERN) announced it will release its third quarter 2026 financial results and business highlights on November 4, 2026, before the market opens, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The company, focused on hematology and blood cancer treatments, highlights its approved drug RYTELO® (imetelstat) for lower-risk myelodysplastic syndromes and ongoing Phase 3 trials for myelofibrosis. The announcement provides details for investors to access the information and participate in the call.

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

https://www.globenewswire.com/news-release/2026/10/21/3385439/35501/en/geron-plans-to-announce-third-quarter-2026-financial-results-on-november-4-2026.html
Geron Corporation announced it will release its third quarter 2026 financial results and business highlights on Wednesday, November 4, 2026, before the market opens. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results. Geron, a hematology-focused biopharmaceutical company, focuses on developing treatments for blood cancers, including its approved medicine RYTELO® (imetelstat) for lower-risk myelodysplastic syndromes.

Geron reports USD 57.48 million revenue: Geron stock sits 39.30 percent below its high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/geron-reports-usd-57-48-million-revenue-geron-stock-sits-39-30-percent/70377464
Geron Corporation reported second-quarter 2026 revenue of USD 57.48 million, an 11.70 percent year-over-year increase, surpassing the consensus estimate. The company expects 2026 RYTELO sales to be between USD 220 million and USD 240 million. Geron's stock price, trading at USD 1.22 on October 20, 2026, is 39.30 percent below its 52-week high, with the next earnings report anticipated on November 4, 2026.

Three new hires got the right to buy Geron shares at $1.17 each; the options vest over four years.

https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-pxgq62m516ej.html
Geron (Nasdaq: GERN) granted stock options to three new employees to purchase an aggregate of 570,000 common shares. The options have an exercise price of $1.17 per share, equal to the closing price on the grant date, and vest over four years, subject to continued employment. This grant was made as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/19/3383857/0/en/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Geron Corporation announced it granted stock options for 570,000 shares of common stock to three new employees as an inducement to employment, effective October 16, 2026. The options have an exercise price of $1.17 per share and vest over four years, subject to continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Advertisement

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/19/3383857/35501/en/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Geron Corporation announced it granted stock options to three new employees to purchase an aggregate of 570,000 shares of common stock, effective October 16, 2026. The grants, made under Nasdaq Listing Rule 5635(c)(4), serve as an inducement for their employment, with an exercise price of $1.17 per share and a four-year vesting schedule. This action aligns with the company's focus as a hematology-focused biopharmaceutical firm.

Five analysts place USD 4.25 target on Geron stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/five-analysts-place-usd-4-25-target-on-geron-stock/70351168
Five analysts have set an average target price of USD 4.25 for Geron stock, significantly higher than its current Nasdaq price of USD 1.17. The company's next reporting date is November 4, 2026, with market capitalization at USD 751.7 million. Investors are looking at these estimates and the forthcoming earnings report as key indicators for the stock's future performance.

Geron Corporation Rings the Nasdaq Stock Market Closing Bell

https://www.nasdaq.com/videos/geron-corporation-rings-nasdaq-stock-market-closing-bell
Geron Corporation, a biopharmaceutical company focused on hematology, rang the Nasdaq Stock Market Closing Bell to celebrate 30 years of being listed on Nasdaq. The ceremony took place at the Nasdaq MarketSite in Times Square, with President and CEO Harout Semerjian ringing the bell. This event highlights the company's long-standing presence on the exchange.

Geron stock trades 38.81 percent below its 52-week high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/geron-stock-trades-38-81-percent-below-its-52-week-high/70332209
Geron stock is trading 38.81 percent below its 52-week high, despite reporting a 11.70 percent increase in second-quarter revenue to USD 57.48 million. The company's Nasdaq quotation was USD 1.23, up 2.94 percent, while it continues to balance commercial expansion with clinical development for imetelstat. Geron's market capitalization stands at USD 787.0 million with a negative price-to-earnings ratio.

Geron Corporation (1GERN.MI) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/1GERN.MI/
This page provides comprehensive financial information for Geron Corporation (1GERN.MI), including its stock price, historical data, company profile, and performance metrics. The company is a commercial-stage biopharmaceutical firm focused on oncology, with several therapeutic products in various phases of clinical trials. Key financial data like market capitalization, volume, and earnings information are also presented.
Advertisement

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

https://www.tradingview.com/news/prnewswire:8b81914c76bda:0-did-geron-corporation-insiders-breach-their-fiduciary-duties-to-shareholders/
The article poses a question regarding whether Geron Corporation insiders breached their fiduciary duties to shareholders. It is a headline-only news item from PR Newswire. No further details are provided within the body of the article.

Geron Corporation Announces Oral Presentations Highlighting

https://www.globenewswire.com/news-release/2026/10/12/3378848/35501/en/geron-corporation-announces-oral-presentations-highlighting-imetelstat-at-international-hematology-congresses-in-europe-and-asia.html
Geron Corporation announced oral and poster presentations highlighting its drug imetelstat for lower-risk myelodysplastic syndromes (LR-MDS) at international hematology congresses in Europe and Asia. These presentations showcase real-world evidence and findings from the Phase 3 IMerge trial, reinforcing growing global scientific engagement with imetelstat and its potential to benefit patients. The data emphasize durable clinical outcomes and manageable safety, with early cytopenias potentially predicting better therapeutic response.

Long term debt to total assets ratio of Geron Corporation – HAN:GON

https://www.tradingview.com/symbols/HAN-GON/financials-statistics-and-ratios/long-term-debt-to-assets/
This article provides financial data for Geron Corporation (HAN:GON) focusing on its long-term debt to total assets ratio. The data is presented within the TradingView platform, showing the ratio's value and change over different periods. The page highlights that the market is closed with no recent trades for the company.

Geron Corporation Announces Oral Presentation

https://www.moomoo.com/news/flash/1000933991/geron-corporation-announces-oral-presentations-highlighting-imetelstat-at-international-hematology
Geron Corporation announced an oral presentation at the European Hematology Association (EHA) 2022 Hybrid Congress. Dr. John Scarlett, Chairman and CEO, will provide an overview of imetelstat, including updated clinical data from the IMerge Phase 2/3 trial in lower risk myelodysplastic syndromes. This presentation highlights the company's progress and the potential of imetelstat in treating hematologic malignancies.

Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

https://www.globenewswire.com/news-release/2026/10/12/3378848/0/en/geron-corporation-announces-oral-presentations-highlighting-imetelstat-at-international-hematology-congresses-in-europe-and-asia.html
Geron Corporation announced that imetelstat, its treatment for lower-risk myelodysplastic syndromes (LR-MDS), will be highlighted in oral and poster presentations at upcoming international hematology congresses in Japan and Germany. These presentations will feature real-world evidence from the U.S. and clinical findings from the Phase 3 IMerge trial, demonstrating the growing global scientific interest and clinical utility of imetelstat in LR-MDS patients. The presentations will cover real-world experience, durable clinical outcomes in Korean patients, and insights into imetelstat's potential to alter disease biology and improve patient outcomes.
Advertisement

Geron to Present Imetelstat Data at 2 Hematology Meetings | GERN Stock News

https://www.stocktitan.net/news/GERN/geron-corporation-announces-oral-presentations-highlighting-q2wolp88w01l.html
Geron (GERN) announced it will present new data on imetelstat, its treatment for lower-risk myelodysplastic syndromes (LR-MDS), at two international hematology congresses. The presentations will include real-world evidence from a U.S. study where approximately 67% of 58 patients remained on therapy at six months, and clinical findings from Korean patients showing prolonged transfusion independence. These presentations highlight growing global interest and evidence supporting imetelstat's efficacy and manageable safety profile.

Geron reports 17 percent revenue growth: Geron stock has a USD 4.25 target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/geron-reports-17-percent-revenue-growth-geron-stock-has-a-usd-4-25-target/70270088
Geron reported a 17% revenue increase in Q2 2026, reaching $57.50 million, and provided 2026 RYTELO revenue guidance of $220.00-240.00 million. Despite commercial progress and a 24% rise in first-half revenue, operating expenses are carefully managed. The company's stock is trading near its yearly low, while analysts have an average target price of $4.25.

Geron Q2 2026 Earnings Call: Complete Transcript

https://www.benzinga.com/news/26/10/62238075/geron-q2-2026-earnings-call-complete-transcript?utm_source=googlefinance
Geron Corporation announced a strong second quarter in 2026, with net revenue increasing 17% year-over-year to $57.5 million, driven by the expansion of Rytelo in the U.S. second-line MDS market. The company projects to reach the mid to high end of its full-year revenue guidance of $220-$240 million and maintains a strong financial position with $327 million in cash. Geron is also exploring European commercialization strategies for Rytelo and is in discussions with regulatory authorities regarding the Phase 3 IMpactMF trial interim analysis.

Geron Corporation stock reports 17 percent revenue growth

https://www.ad-hoc-news.de/boerse/news/corporate-news/geron-corporation-stock-reports-17-percent-revenue-growth/70241986
Geron Corporation reported a 17 percent year-over-year increase in Q2 2026 net revenue, reaching $57.5 million, its highest quarterly RYTELO revenue to date. Despite this commercial growth, the company recorded a net loss of $16.68 million and negative operating cash flow, highlighting the ongoing tension between accelerating revenue and cash consumption. Analysts maintain a "Buy" consensus with a $4.25 price target, emphasizing the importance of future revenue conversion and progress toward profitability.

Shares replace cash fees for Geron (GERN) director Robert J. Spiegel, who acquired 6,351 shares.

https://www.stocktitan.net/sec-filings/GERN/form-4-geron-corp-insider-trading-activity-4c768f08b59d.html
Geron Corp (GERN) director Robert J. Spiegel acquired 6,351 common shares on September 30, 2026, as compensation for quarterly board retainer and committee fees, rather than receiving cash. The share count was determined by the closing price of $1.23 on that day. Following this transaction, Spiegel directly holds 212,161 shares in the company.
Advertisement

EBIT per share of Geron Corporation – HAN:GON

https://www.tradingview.com/symbols/HAN-GON/financials-statistics-and-ratios/ebit-per-share/
The article focuses on the EBIT (Earnings Before Interest and Taxes) per share for Geron Corporation, listed under the ticker HAN:GON on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content provided is primarily a placeholder for financial data, with no specific values or changes detailed.

Total common shares outstanding of Geron Corporation – HAN:GON

https://www.tradingview.com/symbols/HAN-GON/financials-statistics-and-ratios/total-shares-outstanding/
This article provides financial information for Geron Corporation (HAN:GON) on the Hannover Stock Exchange, specifically focusing on its total common shares outstanding. It appears to be a data point from a financial platform like TradingView, indicating a value for the shares outstanding over a given period.

Geron Corporation Revenue Breakdown – HAN:GON

https://www.tradingview.com/symbols/HAN-GON/financials-segments/
Geron Corporation reported a revenue of 156.56 million EUR last year, with its Therapeutic Products for Oncology segment being the sole and top-performing contributor. This revenue primarily originated from the United States, marking a significant increase from the 74.37 million EUR reported in the previous year.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

https://www.prnewswire.com/news-releases/geron-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-geron-corporation---gern-302890626.html
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Geron Corporation (NasdaqGS: GERN) and its officers and directors. This follows a securities class action lawsuit against Geron, alleging that the company failed to disclose material information regarding the growth of its primary product, imetelstat (Rytelo), which reportedly flattened due to seasonality, competition, and other factors. KSF is investigating whether Geron's leadership breached fiduciary duties or violated state or federal laws.

Law firm investigates Geron Corp officers for possible shareholder duty breaches

https://pluang.com/en/news-feed/apakah-petinggi-geron-corporation-lakukan-pelanggaran-tanggung-jawab
Halper Sadeh LLC is investigating whether officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. The law firm is seeking to provide long-term Geron stockholders with corporate governance reforms, financial incentives, or other relief, operating on a contingency fee basis. This investigation comes as part of a broader health sector market snapshot provided by Pluang, noting mixed performance among health stocks.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement